China Resources Pharmaceutical Group Ltd.
3320
주식 순위
#4275
China Resources Pharmaceutical Group Limited, an investment holding company,... China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese medicines, and biological drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular diseases, alimentary tract, endocrine diseases, respiratory diseases, orthopedics, nephrology, rheumatology and immunology, medical nutrition, pediatrics, genitourinary system, dermatological diseases, blood products, therapeutic infusions, antitumor drugs, medicine for cough and cold, anti-infection drugs, and psychoneurosis. It also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical/medical device manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, the company is involved in property holding activities, as well as operates retail pharmacies under the Teck Soon Hong brands. It distributes its products under the 999, Dong-E-E-Jiao, Double Crane, Zizhu, Jiangzhong, Boya, and Kun Zhong Yao to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.
주가
$0.58910029
마지막 동기화: 2026-10-16
시가총액
$3.70B
변동 (1일)
-2.23%
변동 (1년)
-3.41%
국가
HK
거래 China Resources Pharmaceutical Group Ltd. (3320)
카테고리
Healthcare
China Resources Pharmaceutical Group Ltd. (3320)의 영업이익률
October 2026 기준 영업이익률 TTM: 4.21%
China Resources Pharmaceutical Group Ltd.의 최신 재무 보고서와 주가에 따르면 현재 영업이익률 (TTM)은 4.21%입니다. 2023년 말 기준 영업이익률은 4.31%였습니다.
China Resources Pharmaceutical Group Ltd.의 영업이익률 기록 (2013 ~ 2026)
매년 말 영업이익률
| 연도 | 영업이익률 | 변화 |
|---|---|---|
| 2026 (TTM) | 4.21% | -10.43% |
| 2024 | 4.70% | 9.05% |
| 2023 | 4.31% | 1.17% |
| 2022 | 4.26% | 8.95% |
| 2021 | 3.91% | -7.57% |
| 2020 | 4.23% | 7.91% |
| 2019 | 3.92% | -28.86% |
| 2018 | 5.51% | 2.42% |
| 2017 | 5.38% | 1.32% |
| 2016 | 5.31% | -1.30% |
| 2015 | 5.38% | -17.48% |
| 2014 | 6.52% | -10.44% |
| 2013 | 7.28% | 0.00% |
유사 기업 또는 경쟁사의 영업이익률
| 회사 | 영업이익률 | 영업이익률 차이 | 국가 |
|---|---|---|---|
| 62.34% | -85.19% |
US
|
|
| 0.00% | - |
SE
|
|
| 0.00% | - |
FR
|
|
| 0.00% | - |
IT
|
|
| 0.77% | -99.82% |
US
|
회사의 영업이익률이란?
영업이익률은 회사의 수익성을 평가하는 핵심 지표입니다. 높은 영업이익률은 일반적으로 긍정적으로 간주되며, 이는 회사가 제품이나 서비스를 생산 비용보다 훨씬 높은 가격에 판매할 수 있음을 보여줍니다. 영업이익률은 회사의 수익을 매출로 나누어 계산합니다.